

Hydrogen-Free Palladium-Catalyzed Intramolecular *anti*-Markovnikov Hydroaminocarbonylation of 2-(1-Methylvinyl)anilines

Tong Ru,^{† a,b,c} Yingtang Ning,^{† a,c} Ding Liu,^{a,c} Tao Yuan,^{a,c} Jiaqi Wang,^{a,c} Fen-Er Chen^{*a,b,c}

[†] These authors contribute equally to this work.

^a. Engineering Center of Catalysis and Synthesis for Chiral Molecules, Fudan University, 200433
Shanghai, China

^b. School of Pharmacy, Fudan University, 200433 Shanghai, China

^c. Shanghai Engineering Center of Industrial Catalysis for Chiral Drugs, 200433 Shanghai, China


* Corresponding author. Email: rfchen@fudan.edu.cn

Table of Contents

1. Supporting Tables and Schemes.	3
Table S1. Effect of Pd precursors, acids and solvents.	3
Table S2. Effect of TsOH concentration.	4
Table S3. Screen of reaction conditions (ratio/temperature/pressure).....	5
Table S4. Effect of catalyst concentration (Pd/L ratio).	6
Table S5. Effect of TsOH concentration.	6
Table S6. Compatibility of aryl iodides.	7
Scheme S1. Unsuccessful substrates.	7
Scheme S2. Attempts of three component reactions. Products from hydroaminocarbonylation were not detected. .	7
Scheme S3. Analysis of reaction progress	8
Scheme S4. Deuterium labelling experiments with additional D ₂ O.	8
Figure. S1 HRMS-ESI spectrum of [H(dppp) ₂ Pd] ⁺	9
2. General information	10
3. General procedure for hydroaminocarbonylation	11
Figure. S2 GC-MS spectrum of curde reaction mixture.	12
4. Synthesis of Substrate	13
4.1 General Procedure for synthesis of 1b-1s, 1u-1z	13
4.2 Synthesis of 1t	13
4.3 General procedure for synthesis of 1ab, 1ac, and 1ae-1ah	14
4.4 Synthesis of 1ad	14
5. Characterization data of substrates	16
6. Characterization data of 4-Methyl-3,4-dihydroquinolin-2(1<i>H</i>)-one.....	26
7. Gram-scale hydroaminocarbonylaion	41
8. Discussions on the alternative CO migratory insertion into the Pd-N bond.	42
Scheme S5. CO migratory insertion.	42
9. Reference	43
10. NMR spectra	45

1. Supporting Tables and Schemes.


Table S1. Effect of Pd precursors, acids and solvents. ^a




Entry	Pd	Solvent	Acid	Yield (%)
1	PdCl ₂	THF	TsOH	n.d.
2	PdBr ₂	THF	TsOH	n.d.
3 ^c	Pd(dppf)Cl ₂	THF	TsOH	5
4	Pd(OCOCF ₃) ₂	Toluene	TsOH	27
5	Pd(OCOCF ₃) ₂	EtOAc	TsOH	>95
6	Pd(OCOCF ₃) ₂	DCE	TsOH	17
7	Pd(OCOCF ₃) ₂	THF	Benzoic acid	n.d.
8	Pd(OCOCF ₃) ₂	THF	CF ₃ COOH	n.d.
9	Pd(OCOCF ₃) ₂	THF	H ₂ SO ₄	n.d.
10	Pd(OCOCF ₃) ₂	THF	HCl	n.d.

[a] Reactions were performed with **1a** (0.25 mmol) with Pd (1.0 mol%), dppp (2 mol%) and acid (4.0 mol%) in corresponding solvent (2.0 ml), 24 h [b] Yields were determined by GC analysis using mesitylene as an internal standard. [c] no ligand.


Table S2. Effect of TsOH concentration.^a



Entry	Acid	Yield (%) ^a
1	4-F-benzenesulfonic acid	84
2	benzenesulfonic acid	84
3	TsOH	85
4	4-OMe-benzenesulfonic acid	91




[a] Reactions were performed with **1a** (0.25 mmol) with Pd(OCOCF₃)₂ (1 mol%), dppp (1 mol%) and TsOH (z mol%) in THF (2.0 ml), 8 h. [b] Yields of **2a** were determined by GC analysis using mesitylene as an internal standard.

Table S3. Screen of reaction conditions (ratio/temperature/pressure). ^a


Entry	X	Y	<i>P</i> (MPa)	<i>T</i> (C°)	Yield (%) ^b
1	1	4	3.0	80	60
2	3	4	3.0	80	98
3	4	4	3.0	80	68
4 ^c	2	1	3.0	80	34
5 ^c	2	2	3.0	80	38
6 ^c	2	4	3.0	80	57
7 ^c	2	8	3.0	80	64
8	2	4	1.0	80	33
9	2	4	2.0	80	77
10	2	4	4.0	80	>95
11	2	4	3.0	60	13
12	2	4	3.0	100	>95

[a] Reactions were performed with **1a** (0.25 mmol) with Pd(OCOCF₃)₂ (1 mol%), dppp (X mol%) and TsOH (Y mol%) in THF (2.0 ml), 24 h [b] Yields were determined by GC analysis using mesitylene as an internal standard. [c] 12 h.

Table S4. Effect of catalyst concentration (Pd/L ratio).^a

Entry	x	y	x:y	Yield (%) ^b
1	0.6	2.4	1:4	20
2	1	2	1:2	38
3	1.5	1.5	1:1	55
4	2	1	2:1	28
5	2.4	0.6	4:1	4




[a] Reactions were performed with **1a** (0.25 mmol) with Pd(OCOCF₃)₂ (x mol%), dppp (y mol%) and TsOH (4.0 mol%) in THF (2.0 ml), 8 h. [b] Yields of **2a** were determined by GC analysis using mesitylene as an internal standard.

Table S5. Effect of TsOH concentration.^a



Entry	x	Yield (%) ^b
1	0.5	n.d
2	1.0	n.d
3	1.5	8
4	2.0	8
5	4.0	21
6	6.0	32
7	8.0	35

[a] Reactions were performed with **1a** (0.25 mmol) with Pd(OCOCF₃)₂ (1 mol%), dppp (1 mol%) and TsOH (z mol%) in THF (2.0 ml), 8 h. [b] Yields of **2a** were determined by GC analysis using mesitylene as an internal standard.


Table S6. Compatibility of aryl iodides.

				
Entry	Additive	Conv. of 1a (%)	Conv. of Additive (%)	Yield of 2a
1		12	19	n.d.
2		14	17	n.d.


[a] Reactions were performed with **1a** (0.25 mmol) with Pd(OCOCF₃)₂ (1 mol%), dppp (1 mol%) and TsOH (z mol%) in THF (2.0 ml), 8 h. [b] Yields and conversions of **2a** were determined by GC analysis using mesitylene as an internal standard.

Scheme S1. Unsuccessful substrates.**Scheme S2.** Attempts of three component reactions. Products from hydroaminocarbonylation were not detected.

Scheme S3. Analysis of reaction progress




Scheme S4. Deuterium labelling experiments with additional D₂O.



Note: The deuterium incorporation for **1a-D** in the reaction is significantly lower than the theoretical limit. This deviation was attributed to the presence of residual water (H₂O) in the reaction medium.

Figure. S1 HRMS-ESI spectrum of $[H(dppp)_2Pd]^+$.



Note: HRMS-ESI (m/z): $[M]^+$ calcd for $[C_{54}H_{53}P_4Pd]^+$: 931.2127, found: 931.2108.

2. General information

Commercial reagents and solvents were ordered from TCI, Bidepharm and Wohua. Reagents and solvents were used as received unless otherwise stated. When necessary, solvents were dried with standard procedures^[1], degassed with N₂ and transferred by syringe. Column chromatography was performed on silica gel (100-200 mesh). Thin layer chromatography (TLC) was performed on EM reagents 0.25 mm silica 60-F plates. NMR spectra were recorded on Bruker ADVANCE III (400 MHz) spectrometer. CDCl₃ was the solvent used for the NMR analysis, with tetramethylsilane as the internal standard. Chemical shifts were reported relative to TMS (0.00 ppm) for ¹H NMR and relative to CDCl₃ (77.16 ppm) for ¹³C NMR. Data are reported as follows: chemical shift [integration, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, m = multiplet), coupling constant(s) in Hertz]. GC-MS analysis was carried out on Angilent 7820A GC system and Angilent 5977B MSD. Melting points were acquired on a Hanon MP450 melting point apparatus. All new products were further characterized by ESI-HRMS. High-resolution mass spectra (HRMS) were recorded on a Bruker microTOF Q III spectrometer with electrospray ionization (ESI).

3. General procedure for hydroaminocarbonylation


The hydroaminocarbonylation reactions were conducted in a batch reactor (Shaanxi Wattcas). In a typical run, Pd(OCOCF₃)₂ (0.83 mg, 2.5×10⁻³ mmol, 1.0 mol%), 1,3-bis(diphenylphosphino)propane (dppp, 2.06 mg, 5.0×10⁻³ mmol, 2.0 mol%, Rh/L = 1:2), *p*-toluenesulfonic acid (TsOH, 1.72 mg, 0.01 mmol, 4.0 mol%, Rh/acid = 1:4) was dissolved in 2.0 ml of tetrahydrofuran (THF). Substrate (0.25 mmol) was added, and the reactor was flushed with carbon monoxide for three times and then charged with 3.0 MPa carbon monoxide. The mixture was stirred for 24 h at 80 °C. The products were analyzed by GC-MS with mesitylene as an internal standard. The solvents were removed under reduced pressure and the residues were purified by column chromatography (eluent: 20% ethyl acetate in petroleum ether).

Qualitative Analysis Report

Data File	20220403-RT-5.D	Sample Name	20220403-RT-5
Sample Type		Position	9
Instrument Name	5977B	User Name	
Acq Method	GEN-01.M	Acquired Time	4/3/2022 3:31:02 PM (UTC+08:00)
IRM Calibration Status	Not Applicable	DA Method	00-20220301.m
Comment			
Expected Barcode		Sample Amount	
Dual Inj Vol	1	TuneName	ATUNE.U
TunePath	D:\MassHunter\GCMS\1\5977\	TuneDateStamp	2022-03-03T09:04:44+08:00
MSFirmwareVersion	6.00.34	OperatorName	
RunCompletedFlag	True	Acquisition Time (Local)	4/3/2022 3:31:02 PM (UTC+08:00)
Acquisition SW Version	MassHunter GC/MS Acquisition B.07.06.2704 18-Jul-2017 Copyright © 1989-2017 Agilent Technologies, Inc.	SingleQuadrupole Driver Version	7.6.0.0
SingleQuadrupole Firmware Version	6.00.34		

Chromatograms

Fragmentor Voltage Collision Energy 0 Ionization Mode EI



Integration Peak List


Peak	Start	RT	End	Height	Area	Area %
1	3.883	3.911	4.034	3120451.89	4924193.88	87.44
2	8.894	8.941	9.074	2934303.81	5631776.18	100

--- End Of Report ---

Figure. S2 GC-MS spectrum of curde reaction mixture.

4. Synthesis of Substrate


4.1 General Procedure for synthesis of **1b-1s**, **1u-1z**



2-Bromoaniline **S1b** (925 mg, 5 mmol, 1.0 eq) was added to a suspension of potassium carbonate (2.07 g, 15 mmol, 3.0 eq), isopropenylboronic acid pinacol ester **S2** (924 mg, 5.5 mmol, 1.1 eq) and Pd(dppf)Cl₂ (91mg, 0.25mmol, 0.025 eq) in a mixture of dioxane (20ml) and H₂O (10ml) via syringe. The mixture of reaction was stirred for 24 h at 90 °C. After cooling to room temperature, the mixture was extracted with ethyl acetate (15 ml × 2). The organic phases were combined, washed with brine, and dried over anhydride Na₂SO₄. The solvent was removed under reduced pressure, and the crude material was purified by silica gel column chromatography (eluent = 20% ethyl acetate in petroleum ether) to give **1b** (640 mg, yield 87%).


1c-1t, **1v-1z** and **1aa** were prepared following the same procedure as **1b**.

4.2 Synthesis of **1t**



To the solution of freshly prepared Cp₂TiMe₂ in toluene ^[21] (0.5 M, 20 ml, 2.0 eq), 1-(2-amino-5-bromophenyl) ethenone **S1u** (1.07 g, 5 mmol, 1.0 eq) was added under nitrogen atmosphere. Then the mixture was heated to 70 C° and stirred for 12 h. Water (10 mL) was added, and the mixture was extracted with ethyl acetate (20 ml ×2). The organic layers were combined and dried over anhydride Na₂SO₄. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: 2% ethyl acetate in petroleum ether) to give 4-bromo-2-(prop-1-en-2-yl) aniline **1u** (360 mg, yield 35%).


4.3 General procedure for synthesis of **1ab**, **1ac**, and **1ae-1ah**.



To a solution of *t*-BuOK (672 mg, 6 mmol, 1.2 eq) in THF (20 ml) at 0 °C, methyltriphenylphosphonium bromide (2.14 g, 6 mmol 1.2 eq) was added. The mixture was stirred under nitrogen atmosphere for 0.5 h. After that, 2-aminophenones **S1ab** (735 mg, 5 mmol, 1.0 eq) in 2.0 ml THF was added via syringe. The reaction was stirred at room temperature until the complete consumption of the starting material as monitored by thin layer chromatography (about 4 h). The solution was concentrated under reduced pressure, and the residue was purified by chromatography on silica gel (eluent: 2% ethyl acetate in petroleum ether) to give the **1ab** (475 mg, yield 66%).


1ac, **1ae-1ah**. were prepared following the same procedure as **1ab**.

4.4 Synthesis of **1ad**




To a solution of methyl 2-(methylamino) benzoate **S1ad-1** (825 mg, 5 mmol, 1.0 eq) in diethyl ether at 0 °C, methylmagnesium bromide (3.0M in diethyl ether, 12.5 mmol, 4.2 ml, 2.5 eq) was added dropwise. The mixture was allowed to warm to room temperature and stirred for 4 h. The reaction was quenched by saturated NaHCO₃, extract with ethyl acetate and washed with brine. The combined organic phases were dried over Na₂SO₄ and concentrated to give the crude 2-(methylamino) α -dimethyl-benzylalcohol **S1ad-2**. TsOH (17.2 mg, 0.1 mmol, 0.02 eq) was added to the solution of the crude 2-(methylamino) α -dimethyl-benzylalcohol **S1ad-2** in toluene (20 ml) and the mixture was refluxed overnight. The solvent was removed by vacuum and the residue was subjected to silica gel chromatography (eluent: 2% ethyl acetate in petroleum ether) to give the N-methyl-2-(prop-1-en-2-yl) aniline (**1ad**) (530 mg, 2-step yield: 72%).

5. Characterization data of substrates




1b

4-Methyl-2-(prop-1-en-2-yl)aniline (1b) ^[3]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 6.92-6.89 (2H, m), 6.65 (1H, d, *J* = 7.8 Hz), 5.31-5.30 (1H, m), 5.07-5.06 (1H, m), 3.74 (2H, brs), 2.27 (3H, s), 2.10-2.09 (3H, m).




1c

5-Methyl-2-(prop-1-en-2-yl)aniline (1c) ^[4]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 6.96 (1H, d, *J* = 7.7 Hz), 6.59 (1H, d, *J* = 7.7 Hz), 6.56 (1H, s), 5.30-5.29 (1H, m), 5.06 (1H, dd, *J* = 2.2, 0.9 Hz), 3.82 (2H, brs), 2.28 (3H, s), 2.08 (3H, dd, *J* = 1.4, 0.9 Hz).



1d


6-Methyl-2-(prop-1-en-2-yl)aniline (1d) ^[3]: light yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.03 (1H, d, *J* = 7.4 Hz), 6.98 (1H, d, *J* = 7.6 Hz), 6.74 (1H, t, *J* = 7.5 Hz), 5.36 (1H, dd, *J* = 2.1, 1.6 Hz), 5.11 (1H, dd, *J* = 2.1, 0.9 Hz), 3.85 (2H, brs), 2.23 (3H, s), 2.13 (3H, s).



1e


4-(tert-butyl)-2-(prop-1-en-2-yl)aniline (1e) ^[5]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.15 (1H, dd, *J* = 8.3, 2.4 Hz), 7.11 (1H, d, *J* = 2.3 Hz), 6.71 (1H, d, *J* = 8.3

Hz), 5.34 (1H, d, $J = 0.6$ Hz), 5.11 (1H, s), 3.78 (2H, brs), 2.14 (3H, s), 1.33 (9H, s).




1f

4-Methoxy-2-(prop-1-en-2-yl)aniline (1f) ^[4]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 6.68-6.65 (3H, m), 5.30 (1H, s), 5.06 (1H, dd, $J = 2.1, 0.9$ Hz), 3.75 (3H, s), 3.59 (2H, brs), 2.08-2.07 (3H, m).




1g

5-Methoxy-2-(prop-1-en-2-yl)aniline (1g) ^[4]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 6.99 (1H, d $J = 8.4$ Hz), 6.34 (1H, dd, $J = 8.4, 2.5$ Hz), 6.28 (1H, d, $J = 2.5$ Hz), 5.29 (1H, s), 5.06 (1H, s), 3.93 (2H, brs), 3.78 (3H, s), 2.08 (3H, s).




1h

4-Trifluoromethoxy-2-(prop-1-en-2-yl)aniline (1h) ^[6]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 6.94-6.91 (2H, m), 6.65 (1H, d, $J = 8.2$ Hz), 5.34 (1H, s), 5.10 (1H, d, $J = 0.7$ Hz), 3.87 (2H, brs), 2.06 (3H, s).




1i

4-Methoxycarbonyl-2-(prop-1-en-2-yl)aniline (1i) ^[7]: light yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.74-7.72 (2H, m), 6.65 (1H, d, $J = 8.9$ Hz), 5.32 (1H, d, $J = 1.3$ Hz), 5.06 (1H, d, $J = 0.8$ Hz), 4.31 (2H, brs), 3.84 (3H, s), 2.06 (3H, s).



1j


5-Methoxycarbonyl-2-(prop-1-en-2-yl)aniline (1j) ^[7]: colorless oil, ¹H NMR (400 MHz, CDCl₃) δ 7.39-7.37 (2H, m), 7.07 (1H, dd, *J* = 7.6, 0.5 Hz), 5.33-5.32 (1H, m), 5.08 (1H, s), 3.95 (2H, brs), 3.88 (3H, s), 2.06 (3H, s).



1k


6-Methoxycarbonyl-2-(prop-1-en-2-yl)aniline (1k): yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.80 (1H, dd, *J* = 8.1, 1.6 Hz), 7.13 (1H, dd, *J* = 7.3, 1.6 Hz), 6.62 (1H, dd, *J* = 8.0, 7.3 Hz), 6.06 (2H, brs), 5.34-5.33 (1H, m), 5.06 (1H, dd, *J* = 2.0, 1.0 Hz), 3.87 (3H, s), 2.05 (1H, s). ¹³C NMR (100 MHz, CDCl₃) δ 169.0, 147.2, 142.9, 132.8, 130.6, 130.2, 116.5, 115.4, 110.6, 51.7, 23.9.

HRMS-ESI (m/z): [M+Na]⁺ calcd for [C₁₁H₁₃NNaO₂]⁺: 214.0838, found: 214.0842.




1l

4-Cyano-2-(prop-1-en-2-yl)aniline (1l) ^[5]: light yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.31-7.27 (2H, m), 6.68 (1H, d, *J* = 8.3 Hz), 5.36-5.35 (1H, m), 5.08 (1H, dd, *J* = 1.7, 0.9 Hz), 4.41 (2H, brs), 2.04 (3H, m).




1m

6-Cyano-2-(prop-1-en-2-yl)aniline (1m) ^[8]: colorless oil, ¹H NMR (400 MHz, CDCl₃) δ 7.29 (1H, dd, *J* = 7.8, 1.5 Hz), 7.18 (1H, dd, *J* = 7.5, 1.5 Hz), 6.70 (1H, t, *J* = 7.7 Hz), 5.37-5.36 (1H, m), 5.08 (1H, dd, *J* = 1.4, 1.0 Hz), 4.63 (2H, brs), 2.05-2.04 (3H, m).




1n

4-Trifluoromethyl-2-(prop-1-en-2-yl)aniline (1n) ^[4]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.31-7.28 (2H, overlapped m), 6.71 (1H, d, *J* = 8.2 Hz), 5.36-5.35 (1H, m), 5.10 (1H, d, *J* = 1.9, 0.9 Hz), 4.14 (2H, brs), 2.08-2.07 (3H, m).




1o

5-Trifluoromethyl-2-(prop-1-en-2-yl)aniline (1o) ^[4]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.12 (1H, d, *J* = 7.9 Hz), 6.97 (1H, d, *J* = 7.9 Hz), 6.92 (1H, s), 5.36-5.35 (1H, m), 5.10-5.09 (1H, m), 4.01 (2H, brs), 2.08-2.07 (3H, dd, *J* = 1.4, 1.0 Hz).



1p


4-Fluoro-2-(prop-1-en-2-yl)aniline (1p) ^[3]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 6.80-6.76 (2H, m), 6.65-6.61 (1H, m), 5.33-5.32 (1H, m), 5.08 (1H, dd, *J* = 1.9, 0.9 Hz), 3.71 (2H, brs), 2.06 (3H, dd, *J* = 1.4, 1.0 Hz).



1q


5-Fluoro-2-(prop-1-en-2-yl)aniline (1q) ^[5]: light yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 6.98 (1H, dd, *J* = 8.4, 6.5 Hz), 6.46-6.38 (2H, m), 5.32-5.31 (1H, m), 5.05

(1H, dd, $J = 2.0, 0.9$ Hz), 3.96 (2H, brs), 2.06 (3H, dd, $J = 1.4, 0.9$ Hz).




1r

6-Fluoro-2-(prop-1-en-2-yl)aniline (1r) ^[9]: colorless oil, ¹H NMR (400 MHz, CDCl₃) δ 6.90 (1H, ddd, $J = 10.9, 8.1, 1.3$ Hz), 6.84 (1H, d, $J = 7.7$ Hz), 6.66 (1H, td, $J = 7.9, 5.4$ Hz), 5.34-5.33 (1H, m), 5.11-5.10 (1H, dd, $J = 1.9, 0.9$ Hz), 3.91 (2H, brs), 2.08 (3H, dd, $J = 1.4, 1.0$ Hz).




1s

4-Chloro-2-(prop-1-en-2-yl)aniline (1s) ^[4]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.03-7.00 (2H, m), 6.63-6.61 (1H, m), 5.32-5.31 (1H, m), 5.07 (1H, dd, 1.9, 0.9 Hz), 3.83 (2H, brs), 2.05 (3H, s).




1t

5-Chloro-2-(prop-1-en-2-yl)aniline (1t) ^[3]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 6.95 (1H, dd, $J = 7.8, 0.5$ Hz), 6.71-6.68 (2H, m), 5.32-5.31 (1H, m), 5.05 (1H, 2.0, 1.0 Hz), 3.91 (2H, brs), 2.05 (3H, dd, $J = 1.4, 1.0$ Hz).




1u

4-Bromo-2-(prop-1-en-2-yl)aniline (1u) ^[3]: light yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.15-7.12 (2H, m), 6.57 (1H, d, $J = 9.1$ Hz), 5.31-5.30 (1H, m), 5.05 (1H, dd, $J = 1.9, 0.9$ Hz), 3.83 (1H, brd), 2.04 (3H, s).



1v


4, 6-Dichloro-2-(prop-1-en-2-yl)aniline (1v) ^[10]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.17 (1H, d, *J* = 2.4 Hz), 6.92 (1H, d, *J* = 2.4 Hz), 5.35-5.34 (1H, m), 5.08 (1H, d, *J* = 1.8, 0.9 Hz), 4.22 (2H, brs), 2.04 (3H, s).



1w

4, 6-Difluoro-2-(prop-1-en-2-yl)aniline (1w): yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 6.69 (1H, ddd, *J* = 11.1, 8.4, 2.8 Hz), 6.61 (1H, ddd, *J* = 9.2, 2.8, 1.7 Hz), 5.35 (1H, s), 5.11 (1H, dd, 1.8, 0.9 Hz), 3.74 (2H, brs), 2.05 (3H, dd, *J* = 1.5, 1.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 154.6 (dd, *J* = 238.0, 12.4 Hz), 151.2 (dd, *J* = 241.0, 12.4 Hz), 141.7, 131.3 (dd, *J* = 8.2, 4.4 Hz), 127.9 (dd, *J* = 12.6, 3.2 Hz), 116.6, 109.9 (dd, *J* = 22.0, 3.4 Hz), 102.2 (dd, *J* = 26.4, 23.5 Hz), 23.5. ¹⁹F NMR (375 MHz, CDCl₃) δ -125.2 (d, *J* = 1.3 Hz), -130.1 (d, *J* = 1.3 Hz).

HRMS-ESI (*m/z*): [M+Na]⁺ calcd for [C₉H₉F₂NNa]⁺: 192.0596, found: 192.0601.




1x

4-Chloro-6-fluoro-2-(prop-1-en-2-yl)aniline (1x): colorless oil, ¹H NMR (400 MHz, CDCl₃) δ 6.92 (1H, dd, *J* = 10.6, 2.3 Hz), 6.83 (1H, m), 5.36-5.34 (1H, m), 5.10 (1H, dd, *J* = 1.8, 0.9 Hz), 3.87 (2H, brs), 2.05 (3H, dd, *J* = 1.4, 1.0 Hz). ¹³C NMR (100


MHz, CDCl₃) δ 151.4 (d, $J = 242.0$ Hz), 141.4 (d, $J = 3.0$ Hz), 131.8 (d, $J = 4.0$ Hz), 130.5 (d, $J = 12.5$ Hz), 123.5 (d, $J = 3.0$ Hz), 121.7 (d, $J = 10.6$ Hz), 116.8, 114.3 (d, $J = 22.6$ Hz), 23.6. ¹⁹F NMR (375 MHz, CDCl₃) δ -131.6.

HRMS–ESI (m/z): [M+Na]⁺ calcd for [C₉H₉ClFNNa]⁺: 208.0300, found:208.0301.



1y


4-Fluoro-6-chloro-2-(prop-1-en-2-yl)aniline (1y) ^[11]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 6.95 (1H, dd, $J = 8.1, 2.9$ Hz), 6.71 (1H, dd, $J = 8.9, 2.9$ Hz), 5.35-5.34 (1H, m), 5.09 (1H, dd, $J = 1.7, 0.9$ Hz), 4.05 (2H, brs), 2.05-2.04 (3H, m).



1z


4, 5, 6-Trifluoro-2-(prop-1-en-2-yl)aniline (1z): colorless oil, ¹H NMR (400 MHz, CDCl₃) δ 6.68 (1H, ddd, $J = 10.6, 7.9, 2.4$ Hz), 5.36-5.35 (1H, m), 5.09 (1H, s), 3.83 (2H, brs), 2.03 (3H, s). ¹³C NMR (100 MHz, CDCl₃) δ 143.3 (ddd, $J = 239.0, 10.3, 3.3$ Hz), 140.93 (dt, $J = 2.4, 1.2$ Hz), 140.6 (ddd, $J = 241.4, 12.0, 3.6$ Hz), 139.2 (ddd, 247.6, 16.2, 13.8 Hz), 129.2 (dd, $J = 9.8, 2.4$ Hz), 124.2 (m), 117.1, 110.5 (dd, $J = 17.9, 3.3$ Hz), 23.6. ¹⁹F NMR (375 MHz, CDCl₃) δ -150.4 (d, $J = 21.7$ Hz), -154.8 (d, $J = 19.7$ Hz), -162.5 (m).

HRMS–ESI (m/z): [M+Na]⁺ calcd for [C₉H₈F₃NNa]⁺: 210.0501, found:210.0498.




1aa


3-(Prop-1-en-2-yl)naphthalen-2-amine (1aa) ^[12]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.65 (1H, d, *J* = 8.1 Hz), 7.55 (1H, d, *J* = 8.3 Hz), 7.50 (1H, s), 7.32 (1H, ddd, *J* = 8.2, 6.8, 1.2 Hz), 7.20 (1H, ddd, *J* = 8.1, 6.8, 1.1 Hz), 6.97 (1H, s), 5.35 (1H, dd, *J* = 2.0, 1.6 Hz), 5.12 (1H, dd, *J* = 2.0, 0.9 Hz), 3.97 (2H, brs), 2.15-2.14 (3H, m).




2-(But-1-en-2-yl)aniline (1ab) ^[6]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.06 (1H, td, *J* = 7.8, 1.6 Hz), 6.98 (1H, dd, *J* = 7.6, 1.5 Hz), 6.72 (2H, m), 5.27 (1H, d, *J* = 3.5, 1.6 Hz), 5.04 (1H, s), 3.84 (2H, brs), 2.37 (2H, q, *J* = 7.4 Hz), 1.06 (3H, t, *J* = 7.4 Hz).



2-(1-Phenylethenyl)aniline (1ac) ^[5]: white solid, m.p. = 77.2-77.5 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.37 (2H, m), 7.35-7.31 (2H, m), 7.20-7.15 (1H, m), 7.13 (1H, dd, *J* = 7.5, 1.5 Hz), 6.80 (1H, td, *J* = 7.4, 1.1 Hz), 6.71 (1H, dd, *J* = 8.0, 0.9 Hz), 5.81 (1H, d, *J* = 1.4 Hz), 5.37 (1H, d, *J* = 1.4 Hz), 3.56 (2H, brs).




N-methyl-2-(prop-1-en-2-yl)aniline (1ad) ^[3]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.21 (1H, ddd, *J* = 8.1, 7.5, 1.6 Hz), 7.05 (1H, dd, *J* = 7.4, 1.6 Hz), 6.72 (1H, td, *J* = 7.4, 1.1 Hz), 6.66 (1H, d, *J* = 8.2 Hz), 5.33-5.31 (1H, m), 5.06 (1H, dd, *J* = 2.2, 0.9 Hz), 4.20 (1H, brs), 2.86 (3H, s), 2.08 (3H, dd, *J* = 1.4, 1.0 Hz).




1ae

***N*-phenyl-2-(prop-1-en-2-yl)aniline (1ae)** ^[13]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.39-7.30 (3H, m), 7.25-7.21 (2H, m), 7.14-7.12 (2H, m), 7.00-6.95 (2H, m), 5.93 (1H, brs), 5.36 (1H, s), 5.13 (1H, s), 2.13 (3H, s).




1af

***N*-(4-methoxyphenyl)-2-(prop-1-en-2-yl)aniline (1af)** ^[13]: yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.14-7.06 (5H, m), 6.90-6.86 (2H, m), 6.83 (1H, td, *J* = 7.4, 1.5 Hz), 5.77 (1H, brs), 5.34-5.33 (1H, m), 5.12-5.11 (1H, m), 3.81 (3H, s), 2.11 (3H, m).



1ag


***N*-(3-methoxyphenyl)-2-(prop-1-en-2-yl)aniline (1ag)**: light yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.38 (1H, m), 7.24-7.19 (3H, m), 6.99-6.95 (1H, m), 6.70-6.68 (1H, m), 6.54-6.51 (1H, m), 5.90 (1H, brs), 5.34 (1H, d, *J* = 1.5 Hz), 5.11-5.10 (1H, m), 3.82 (3H, s), 2.11 (3H, s). ¹³C NMR (100 MHz, CDCl₃) δ 145.0, 144.0, 139.1, 134.1, 130.2, 128.9, 127.8, 121.1, 118.1, 116.3, 110.4, 106.1, 103.4, 55.3, 24.0. HRMS-ESI (*m/z*): [M+Na]⁺ calcd for [C₁₆H₁₄N₂Na]⁺: 262.3072, found: 262.3077.



1ah


4-((2-(Prop-1-en-2-yl)phenyl)amino)benzonitrile (1ah): yellow oil, ¹H NMR (400

MHz, CDCl₃) δ 7.49-7.45 (2H, m), 7.34 (1H, dd, *J* = 8.0, 1.1 Hz), 7.26-7.22 (2H, m), 7.10 (1H, td, *J* = 7.5, 1.3 Hz), 6.97-6.93 (2H, m), 6.07 (1H, brs), 5.28-5.27 (1H, m), 5.00 (1H, dd, *J* = 1.9, 0.9 Hz), 2.01 (3H, s). ¹³C NMR (100 MHz, CDCl₃) δ 148.4, 143.5, 136.9, 136.4, 133.9, 129.4, 128.1, 124.1, 121.5, 120.1, 116.7, 115.0, 101.6, 24.0. HRMS–ESI (*m/z*): [M+Na]⁺ calcd for [C₁₆H₁₄N₂Na]⁺: 257.1049, found: 257.1046.




2-(Prop-1-en-2-yl-3,3,3-*d*3)-aniline (1a-CD₃): **1a-CD₃** was prepared following the literature procedure ^[9]. ¹H NMR (400 MHz, CDCl₃) δ 7.06–7.01 (2H, m), 6.74–6.65 (2H, m), 5.27 (1H, s), 5.08 (1H, d, *J* = 2.0 Hz), 3.75 (brs, 2H), 2.02 (0.48H, s).


6. Characterization data of 4-Methyl-3,4-dihydroquinolin-2(1H)-one



4-Methyl-3,4-dihydroquinolin-2(1H)-one (2a) ^[15]: white solid, m.p. = 113.4-115.0 C°, 38.3 mg, 95%, ¹H NMR (400 MHz, CDCl₃) δ 9.65 (1H, brs), 7.20-7.15 (2H, m), 7.02 (1H, t, *J* = 7.4 Hz), 6.89 (1H, d, *J* = 7.7 Hz), 3.16-3.11 (1H, m), 2.74 (1H, dd, *J* = 16.1, 5.5 Hz), 2.44 (1H, dd, *J* = 16.1, 7.1 Hz), 1.31 (3H, d, *J* = 5.9 Hz), ¹³C NMR (100 MHz, CDCl₃) δ 172.2, 136.6, 128.7, 127.6, 126.6, 123.4, 115.9, 38.4, 30.8, 19.9.




4,6-Dimethyl-3,4-dihydroquinolin-2(1H)-one (2b) ^[15]: white solid, m.p. = 120.5-122.0 C°, 31.4 mg, 72%, ¹H NMR (400 MHz, CDCl₃) δ 9.43 (1H, s), 6.98 (2H, m), 6.77 (2H, d, *J* = 7.8 Hz), 3.08 (1H, m), 2.72 (1H, dd, *J* = 16.1, 5.8 Hz), 2.41 (2H, dd, *J* = 16.1, 7.1 Hz), 2.30 (3H, s), 1.30 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 171.9, 134.1, 132.9, 128.7, 128.0, 127.2, 115.8, 38.5, 30.8, 21.0, 20.0.




4,7-dimethyl-3,4-dihydroquinolin-2(1H)-one (2c) ^[15]: white solid, m.p. = 111.6-113.2 C°, 38.0 mg, 87%, ¹H NMR (400 MHz, CDCl₃) δ 9.81 (1H, brs), 7.07 (1H, d, *J* = 7.6 Hz), 6.83 (1H, d, *J* = 7.6 Hz), 6.73 (1H, s), 3.12-3.07 (1H, m), 2.73 (1H, dd, *J* = 16.1, 5.8 Hz), 2.42 (2H, dd, *J* = 16.1, 7.3, Hz), 2.30 (3H, s), 1.30 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 172.5, 137.6, 136.5, 126.3, 125.8, 124.1, 116.5, 38.6,

30.4, 21.1, 20.0.




4,9-Dimethyl-3,4-dihydroquinolin-2(1H)-one (2d) ^[16]: white solid, m.p. = 127.5-128.8 C°, 39.3 mg, 90%, ¹H NMR (400 MHz, CDCl₃) δ 8.18 (1H, brs), 7.06-7.03 (2H, m), 6.93 (1H, d, *J* = 7.5 Hz), 3.15-3.08 (1H, m), 2.71 (1H, dd, *J* = 15.9, 5.7 Hz), 2.42 (2H, dd, *J* = 15.9, 6.9 Hz), 2.28 (3H, s), 1.29 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 171.3, 134.8, 129.1, 128.9, 124.5, 123.3, 123.0, 38.4, 31.1, 19.8, 17.1.




6-(Tert-butyl)-4-methyl-3,4-dihydroquinolin-2(1H)-one (2e): white solid, m.p. = 121.0-122.2 C°, 33.5 mg, 62%, ¹H NMR (400 MHz, CDCl₃) δ 9.16 (1H, brs), 7.20-7.18 (2H, m), 6.80 (1H, d, *J* = 8.7 Hz), 3.16-3.08 (1H, m), 2.74 (1H, dd, *J* = 16.1, 5.9 Hz), 2.44 (1H, dd, *J* = 16.1, 6.7 Hz), 1.31 (3H, d, *J* = 7.0 Hz), 1.31 (9H, s), ¹³C NMR (100 MHz, CDCl₃) δ 171.8, 146.4, 134.0, 128.3, 124.4, 123.6, 115.5, 38.5, 34.5, 31.6, 31.2, 20.1.

HRMS-ESI (m/z): [M+Na]⁺ calcd for [C₁₄H₁₉NNaO]⁺: 240.1359, found: 240.1360.




6-Methoxy-4-methyl-3,4-dihydroquinolin-2(1H)-one (2f) ^[16]: white solid, m.p.= 135.2-136.8 C°, 41.6 mg, 86%, ¹H NMR (400 MHz, CDCl₃) δ 9.42 (1H, brs), 6.81-6.69 (3H, m), 3.78 (3H, s), 3.11-3.05 (1H, m), 2.70 (1H, dd, *J* = 16.1, 5.7 Hz), 2.40 (1H, dd,

$J = 16.1, 7.3$ Hz), 1.30 (3H. d, $J = 7.0$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 171.6, 155.9, 130.3, 130.2, 116.6, 112.8, 112.1, 55.7, 38.3, 31.1, 19.8.




7-Methoxy-4-methyl-3,4-dihydroquinolin-2(1H)-one (2g) ^[16]: white solid, m.p. = 109.0-111.0 $^{\circ}\text{C}$, 35.8 mg, yield 75%, ^1H NMR (400 MHz, CDCl_3) δ 9.19 (1H, brs), 7.08 (1H, d, $J = 8.4$ Hz), 6.56 (1H, d, $J = 8.3$ Hz), 6.41 (1H, s), 3.78 (3H, s), 3.09-3.04 (1H, m), 2.71 (1H, dd, $J = 16.1, 5.8$ Hz), 2.40 (1H, dd, $J = 16.1, 7.5$ Hz), 1.29 (3H. d, $J = 6.9$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 172.1, 159.3, 137.6, 127.4, 121.1, 108.6, 101.8, 55.5, 38.8, 30.1, 20.1.




4-Methyl-6-(trifluoromethoxy)-3,4-dihydroquinolin-2(1H)-one (2h): white solid, m.p. = 113.3-115.3 $^{\circ}\text{C}$, 55.0 mg, 90%, ^1H NMR (400 MHz, CDCl_3) δ 9.81 (1H, brs), 7.06-7.03 (2H, m), 6.89 (1H, d, $J = 8.4$ Hz), 3.16-3.11 (1H, m), 2.74 (1H, dd, $J = 16.2, 5.9$ Hz), 2.43 (1H, dd, $J = 16.2, 7.6$ Hz), 1.32 (3H. d, $J = 7.0$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 171.9, 144.8, 135.3, 130.3, 120.5 (q, $J = 256.7\text{Hz}$), 120.3, 119.7 116.7, 37.8, 30.7, 19.5. ^{19}F NMR (375 MHz, CDCl_3) δ -58.2.

HRMS-ESI (m/z): $[\text{M}+\text{Na}]^+$ calcd for $[\text{C}_{11}\text{H}_{10}\text{F}_3\text{NNaO}_2]^+$: 268.0556, found: 268.0558.




Methyl 4-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-carboxylate (2i): white solid, m.p. = 184.0-185.8 C°, 47.0 mg, 85%, ¹H NMR (400 MHz, CDCl₃) δ 9.84 (1H, brs), 7.88 (1H, s), 7.86 (1H, d, *J* = 8.6 Hz), 6.91 (1H, d, *J* = 8.1 Hz), 3.89 (3H, s), 3.20-3.15 (1H, m), 2.76 (1H, dd, *J* = 16.3, 5.7 Hz), 2.45 (1H, dd, *J* = 16.2, 7.2 Hz), 1.33 (3H, d, *J* = 7.0 Hz), ¹³C NMR (100 MHz, CDCl₃) δ 172.3, 166.8, 140.7, 129.6, 128.5, 128.4, 125.1, 115.7, 52.2, 38.2, 30.6, 19.8.

HRMS-ESI (m/z): [M+Na]⁺ calcd for [C₁₂H₁₃NNaO₃]⁺: 242.0788, found:242.0788.



Methyl 4-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-7-carboxylate (2j): white solid, m.p. = 159.0-160.5 C°, 48.5 mg, 89%, ¹H NMR (400 MHz, CDCl₃) δ 9.37 (1H, brs), 7.68 (1H, dd, *J* = 7.9, 1.6 Hz), 7.54 (1H, d, *J* = 1.6 Hz), 7.25 (1H, d, *J* = 7.9 Hz), 3.90 (3H, s), 3.19-3.14 (1H, m), 2.75 (1H, dd, *J* = 16.2, 5.9 Hz), 2.45 (1H, dd, *J* = 16.2, 7.2 Hz), 1.32 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 171.5, 166.7, 136.9, 133.9, 129.7, 126.7, 124.7, 116.7, 52.4, 38.0, 31.0, 19.7.


HRMS-ESI (m/z): [M+Na]⁺ calcd for [C₁₂H₁₃NNaO₃]⁺: 242.0788, found:242.0787.



Methyl 4-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-8-carboxylate (2k): white

solid, m.p. = 41.1-42.1 C°, 21.0 mg, 39%, ¹H NMR (400 MHz, CDCl₃) δ 10.49 (1H, brs), 7.87 (1H, dd, *J* = 8.0, 1.3 Hz), 7.36 (1H, d, *J* = 7.4 Hz), 7.01 (1H, t, *J* = 7.8 Hz), 3.90 (3H, s), 3.17-3.12 (1H, m), 2.71 (1H, dd, *J* = 16.2, 5.9 Hz), 2.42 (1H, dd, *J* = 16.2, 6.7 Hz), 1.30 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 170.4, 167.7, 139.5, 131.8, 129.9, 129.5, 121.9, 113.4, 52.4, 37.8, 31.1, 20.0.


HRMS–ESI (m/z): [M+Na]⁺ calcd for [C₁₂H₁₃NNaO₃]⁺: 242.0788, found: 242.0792.



2l

4-Methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-carbonitrile (2l): white solid, m.p. = 241.1-242.6 C°, 40.5 mg, 87%, ¹H NMR (400 MHz, CDCl₃) δ 9.27 (1H, brs), 7.50-7.48 (2H, m), 6.92-6.90 (1H, m), 3.22-3.14 (1H, m), 2.76 (1H, dd, *J* = 16.4, 5.9 Hz), 2.47 (1H, dd, *J* = 16.4, 7.6 Hz), 1.34 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 171.5, 140.5, 132.2, 130.8, 129.7, 119.1, 116.3, 106.7, 37.9, 30.6, 19.6.


HRMS–ESI (m/z): [M+Na]⁺ calcd for [C₁₁H₁₀N₂NaO]⁺: 209.0685, found: 209.0688.



2m


4-Methyl-2-oxo-1,2,3,4-tetrahydroquinoline-8-carbonitrile (2m): white solid, m.p. = 145.6-147.4 C°, 20.5 mg, 44%, ¹H NMR (400 MHz, CDCl₃) δ 8.01 (1H, brs), 7.46-7.41 (2H, m), 7.08 (1H, t, *J* = 7.7 Hz), 3.21-3.16 (1H, m), 2.77 (1H, dd, *J* = 16.3, 5.81 Hz), 2.48 (1H, dd, *J* = 16.3, 7.1 Hz), 1.32 (3H, d, *J* = 7.1 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 169.7, 139.5, 131.5, 130.9, 130.0, 123.3, 115.8, 98.7, 37.9, 31.0, 19.7.

HRMS–ESI (m/z): [M+Na]⁺ calcd for [C₁₁H₁₀N₂NaO]⁺: 209.0685, found: 209.0687.




2n

4-Methyl-6-(trifluoromethyl)-3,4-dihydroquinolin-2(1H)-one (2n) ^[17]: white solid, m.p. = 113.8-115.0 C°, 49.8 mg, 87%, ¹H NMR (400 MHz, CDCl₃) δ 10.12 (1H, brs), 7.44-7.42 (2H, m), 6.98 (1H, d, *J* = 8.2 Hz), 3.23-3.15 (1H, m), 2.77 (1H, dd, *J* = 16.3, 5.9 Hz), 2.47 (1H, dd, *J* = 16.3, 7.3 Hz), 1.35 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 172.5, 139.6, 129.1, 125.5 (q, *J* = 32.6 Hz), 125.0 (q, *J* = 3.8 Hz), 124.3 (q, *J* = 271.6 Hz), 123.8 (q, *J* = 3.7 Hz), 116.0, 38.0, 30.7, 19.7. ¹⁹F NMR (400 MHz, CDCl₃) δ -61.8.



2o


4-Methyl-7-(trifluoromethyl)-3,4-dihydroquinolin-2(1H)-one (2o) ^[18]: white solid, m.p. = 163.6-165.4 C°, 49.9 mg, 87%, ¹H NMR (400 MHz, CDCl₃) δ 10.05 (1H, brs), 7.31-7.26 (2H, m), 7.13 (1H, s), 3.22-3.17 (1H, m), 2.77 (1H, dd, *J* = 5.9, 16.3 Hz), 2.47 (1H, dd, *J* = 7.1, 16.3 Hz), 1.34 (3H, d, *J* = 7.1 Hz), ¹³C NMR (100 MHz, CDCl₃) δ 172.2, 137.2, 132.6, 130.1 (q, *J* = 32.8 Hz), 127.2, 123.9 (q, *J* = 272.1 Hz), 120.1 (q, *J* = 3.9 Hz), 112.7 (q, *J* = 3.7 Hz), 37.9, 30.8, 19.7. ¹⁹F NMR (375 MHz, CDCl₃) δ -62.5




2p

6-Fluoro-4-methyl-3,4-dihydroquinolin-2(1H)-one (2p): white solid, m.p. = 152.3-

153.8 C°, 41.1 mg, 92%, ¹H NMR (400 MHz, CDCl₃) δ 9.89 (1H, brs), 6.91-6.84 (3H, m), 3.13-3.08 (1H, m), 2.71 (1H, dd, *J* = 16.2, 5.7 Hz), 2.40 (1H, dd, *J* = 16.2, 7.7 Hz), 1.3 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 172.0, 159.1 (d, *J* = 241.8 Hz), 132.8 (d, *J* = 2.4 Hz), 130.7 (d, *J* = 7.2 Hz), 116.9 (d, *J* = 8.2 Hz), 114.1 (d, *J* = 22.8 Hz), 113.5 (d, *J* = 23.3 Hz), 38.0, 30.8, 19.6. ¹⁹F NMR (375 MHz, CDCl₃) δ -119.8. HRMS-ESI (m/z): [M+Na]⁺ calcd for [C₁₀H₁₀FNNaO]⁺: 202.0639, found: 202.0641.




7-Fluoro-4-methyl-3,4-dihydroquinolin-2(1H)-one (2q): white solid, m.p. = 100.0-101.9 C°, 39.6 mg, 91%, ¹H NMR (400 MHz, CDCl₃) δ 9.83 (1H, brs), 7.12 (1H, t, *J* = 7.0 Hz), 6.70 (1H, t, *J* = 8.4 Hz), 6.63 (1H, d, *J* = 9.4 Hz), 3.13-3.08 (1H, m), 2.73 (1H, d, *J* = 16.2, 5.7 Hz), 2.42 (1H, *J* = 16.2, 7.2 Hz), 1.29 (3H, d, *J* = 6.9 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 172.4, 162.2 (d, *J* = 244.4 Hz), 138.0 (d, *J* = 10.5 Hz), 127.8 (d, *J* = 9.3 Hz), 124.4 (d, *J* = 3.1 Hz), 109.8 (d, *J* = 21.2 Hz), 103.4 (d, *J* = 25.4 Hz), 38.4, 30.2, 20.0. ¹⁹F NMR (375 MHz, CDCl₃) δ -114.8. HRMS-ESI (m/z): [M+Na]⁺ calcd for [C₁₀H₁₀FNNaO]⁺: 202.0639, found: 202.0642.




8-Fluoro-4-methyl-3,4-dihydroquinolin-2(1H)-one (2r)^[19]: white solid, m.p. = 133.9-135.4 C°, 40.2mg, 90%, ¹H NMR (400 MHz, CDCl₃) δ 8.54 (1H, brs), 6.95 (3H, m), 3.18-3.13 (1H, m), 2.74 (1H, d, *J* = 16.2, 5.8 Hz), 2.44 (1H, *J* = 16.2, 7.3 Hz), 1.29 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 170.4, 150.0 (d, *J* = 243.8 Hz), 131.1,

125.0 (d, $J = 12.0$ Hz), 123.1 (d, $J = 7.4$ Hz), 121.8 (d, $J = 3.2$ Hz), 113.9 (d, $J = 18.3$ Hz), 38.2, 30.9, 19.8. ^{19}F NMR (375 MHz, CDCl_3) δ -134.3.



2s


6-Chloro-4-methyl-3,4-dihydroquinolin-2(1H)-one (2s) ^[20]: white solid, m.p. = 167.2-167.9 C°, 42.5 mg, 87%, ^1H NMR (400 MHz, CDCl_3) δ 9.94 (1H, br s), 7.16 (1H, s), 7.13 (1H, d, $J = 8.6$ Hz), 6.83 (1H, d, $J = 8.2$ Hz), 3.12-3.08 (1H, m), 2.71 (1H, dd, $J = 16.1, 5.4$ Hz), 2.41 (1H, dd, $J = 16.1, 7.3$ Hz), 1.30 (3H, d, $J = 6.7$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 172.1, 135.3, 130.4, 128.4, 127.5, 126.7, 117.1, 38.1, 30.7, 19.7.



2t

7-Chloro-4-methyl-3,4-dihydroquinolin-2(1H)-one (2t): white solid, m.p. = 139.4-141.2 C°, 41.5 mg, 86%, ^1H NMR (400 MHz, CDCl_3) δ 9.69 (1H, brs), 7.10 (1H, d, $J = 8.1$ Hz), 6.97 (1H, dd, $J = 8.1, 2.0$ Hz), 6.89 (1H, d, $J = 2.0$ Hz), 3.15-3.06 (1H, m), 2.73 (1H, dd, $J = 16.2, 5.9$ Hz), 2.43 (1H, dd, $J = 16.2, 7.3$ Hz), 1.29 (3H, d, $J = 7.0$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 172.1, 137.7, 133.1, 127.7, 127.2, 123.3, 115.9, 38.2, 30.4, 19.8.


HRMS-ESI (m/z): $[\text{M}+\text{Na}]^+$ calcd for $[\text{C}_{10}\text{H}_{10}\text{ClNNaO}]^+$: 218.0343, found: 218.0339.




2u

6-Bromo-4-methyl-3,4-dihydroquinolin-2(1H)-one (2u) ^[16]: white solid, m.p. =


172.0-174.0 C°, 42.5 mg, yield 39%, ¹H NMR (400 MHz, CDCl₃) δ 8.74 (1H, brs), 7.32 (1H, d, *J* = 2.0 Hz), 7.29 (1H, dd, *J* = 8.3, 2.1 Hz), 6.70 (1H, d, *J* = 8.3 Hz), 3.16-3.07 (1H, m), 2.71 (1H, dd, *J* = 16.2, 5.8 Hz), 2.41 (1H, dd, *J* = 16.2, 7.4 Hz), 1.30 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 171.2, 135.7, 131.0, 130.5, 129.7, 117.2, 115.9, 38.1, 30.8, 19.7.



6,8-Dichloro-4-methyl-3,4-dihydroquinolin-2(1H)-one (2v): white solid, m.p. = 109.9-111.2 C°, 48.5 mg, 85%, ¹H NMR (400 MHz, CDCl₃) δ 7.87 (1H, brs), 7.25 (1H, d, *J* = 2.2 Hz), 7.10 (1H, d, *J* = 2.2 Hz), 3.17-3.09 (1H, m), 2.71 (1H, dd, *J* = 16.2, 5.8 Hz), 2.43 (1H, dd, *J* = 16.2, 7.2 Hz), 1.30 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 169.6, 132.2, 131.7, 128.2, 127.5, 125.6, 120.3, 37.9, 31.4, 19.6. HRMS-ESI (m/z): [M+Na]⁺ calcd for [C₁₀H₁₀Cl₂NNaO]⁺: 251.9953, found: 251.9960.




6,8-Difluoro-4-methyl-3,4-dihydroquinolin-2(1H)-one (2w): white solid, m.p. = 177.9-178.9 C°, 44.4 mg, yield 90%, ¹H NMR (400 MHz, CDCl₃) δ 8.64 (1H, brs), 6.77-6.72 (2H, m), 3.17-3.09 (1H, m), 2.72 (1H, dd, *J* = 16.2, 5.7 Hz), 2.43 (1H, dd, *J* = 16.2, 7.8 Hz), 1.30 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 170.0, 158.0 (dd, *J* = 244.4, 11.5 Hz), 149.6 (dd, *J* = 246.6, 12.4 Hz), 132.0 (dd, *J* = 8.3, 2.7 Hz), 121.4 (dd, *J* = 12.1, 3.5 Hz), 109.0 (dd, *J* = 23.0, 3.5 Hz), 102.3 (dd, *J* = 26.8, 22.4 Hz). ¹⁹F NMR (400 MHz, CDCl₃) δ -117.2 (d, *J* = 2.9 Hz), -130.4 (d, *J* = 2.9 Hz). HRMS-ESI (m/z): [M+Na]⁺ calcd for [C₁₀H₉F₂NNaO]⁺: 220.0544, found: 220.0548.




6-Chloro-8-fluoro-4-methyl-3,4-dihydroquinolin-2(1H)-one (2x): white solid, m.p. = 179.9-181.1 C°, 31.5 mg, 59%, ¹H NMR (400 MHz, CDCl₃) δ 8.30 (1H, brs), 7.02 (1H, dd, *J* = 9.8, 2.1 Hz), 6.99 (1H, brs), 3.17-3.12 (1H, m), 2.73 (1H, dd, *J* = 16.3, 5.8 Hz), 2.44 (1H, dd, *J* = 16.3, 7.6 Hz), 1.31 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 169.8, 149.6 (d, *J* = 247.2 Hz), 132.1 (d, *J* = 2.2 Hz), 127.8 (d, *J* = 9.7 Hz), 123.9 (d, *J* = 12.1 Hz), 122.3 (d, *J* = 3.3 Hz), 114.7 (d, *J* = 21.8 Hz), 38.1, 31.1 (d, *J* = 2.3 Hz), 19.6. ¹⁹F NMR (375 MHz, CDCl₃) δ -131.8.

HRMS-ESI (m/z): [M+Na]⁺ calcd for [C₁₀H₉ClFNNaO]⁺: 236.0249, found: 236.0252.




8-Chloro-6-fluoro-4-methyl-3,4-dihydroquinolin-2(1H)-one (2y): white solid, m.p. = 131.3-133.1 C°, 37.0 mg, 70%, ¹H NMR (400 MHz, CDCl₃) δ 7.84 (1H, brs), 7.00 (1H, dd, *J* = 8.0, 2.7 Hz), 6.87 (1H, dd, *J* = 8.5, 2.6 Hz), 3.16-3.10 (1H, m), 2.71 (1H, dd, *J* = 16.2, 5.7 Hz), 2.42 (1H, dd, *J* = 16.2, 7.5 Hz), 1.30 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 169.6, 158.0 (d, *J* = 245.4 Hz), 131.9 (d, *J* = 7.6 Hz), 129.9 (d, *J* = 3.1 Hz), 120.0 (d, *J* = 10.8 Hz), 114.9 (d, *J* = 26.0 Hz), 112.7 (d, *J* = 23.0 Hz), 37.9, 31.5, 19.4. ¹⁹F NMR (375 MHz, CDCl₃) δ -118.1.

HRMS-ESI (m/z): [M+Na]⁺ calcd for [C₁₀H₉ClFNNaO]⁺: 236.0249, found: 236.0251.




2z

6,7,8-Trifluoro-4-methyl-3,4-dihydroquinolin-2(1H)-one (2z): white solid, m.p. = 138.5-140.2 C°, 47.0 mg, 87%, ¹H NMR (400 MHz, CDCl₃) δ 8.22 (1H, brs), 6.84 (1H, ddd, *J* = 9.7, 7.3, 2.0 Hz), 3.14-3.09 (1H, m), 2.73 (1H, dd, *J* = 16.3, 5.7 Hz), 2.43 (1H, dd, *J* = 16.3, 7.9 Hz), 1.30 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 169.6, 146.6 (ddd, *J* = 245.7, 10.2, 2.8 Hz), 139.3 (ddd, *J* = 248.0, 13.0, 3.6 Hz), 139.0 (ddd, *J* = 249.9, 16.7, 13.2 Hz), 124.7 (ddd, *J* = 5.9, 4.1, 1.0 Hz), 122.6 (dd, *J* = 9.5, 3.1 Hz), 109.6 (dd, *J* = 19.0, 3.5 Hz), 38.1, 30.8, 19.5. ¹⁹F NMR (375 MHz, CDCl₃) δ -141.9 (dd, *J* = 1.4, 21.1 Hz), -153.4 (dd, *J* = 1.5, 19.8 Hz), -161.4 (dd, *J* = 20.0, 21.0 Hz). HRMS-ESI (*m/z*): [M+Na]⁺ calcd for [C₁₀H₈F₃NNaO]⁺: 238.0450, found: 238.0453.




2aa

4-Methyl-3,4-dihydrobenzo[g]quinolin-2(1H)-one (2aa): white solid, m.p. = 163.5-163.9 C°, 47.5 mg, 90%, ¹H NMR (400 MHz, CDCl₃) δ 9.64 (1H, brs), 7.76 (1H, d, *J* = 8.3 Hz), 7.73 (1H, d, *J* = 8.4 Hz), 7.65 (1H, s), 7.44-7.35 (2H, m), 7.26 (1H, s), 3.36-3.28 (1H, m), 2.83 (1H, dd, *J* = 16.1, 5.5 Hz), 2.52 (1H, dd, *J* = 16.1, 7.8 Hz), 1.44 (3H, d, *J* = 7.0 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 172.2, 135.1, 133.1, 130.5, 129.8, 127.6, 126.9, 126.4, 125.4, 124.8, 111.7, 38.7, 31.2, 20.1. HRMS-ESI (*m/z*): [M+Na]⁺ calcd for [C₁₄H₁₃NNaO]⁺: 234.0895, found: 234.0896.




2ab

4-Ethyl-3,4-dihydroquinolin-2(1H)-one (2ab)^[21]: white solid, m.p. = 125.6-127.1 C°, 27.0 mg, 60% ¹H NMR (400 MHz, CDCl₃) δ 9.02 (1H, brs), 7.20-7.14 (2H, m), 7.00 (1H, td, *J* = 7.4, 1.1 Hz), 6.84 (1H, d, *J* = 7.8 Hz), 2.88-2.82 (1H, m), 2.77 (1H, dd, *J* = 16.0, 6.2 Hz), 2.56 (1H, dd, *J* = 16.0, 3.8 Hz), 1.72-1.54 (2H, m), 0.94 (3H, t, *J* = 7.4 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 171.9, 136.6, 128.1, 127.6, 127.5, 123.1, 115.9, 38.0, 35.9, 27.1, 11.5.



2ac


4-Phenyl-3,4-dihydroquinolin-2(1H)-one (2ac)^[21]: white solid, m.p. 173.2-173.9 C°, 32.0 mg, 58%, ¹H NMR (400 MHz, CDCl₃) δ 9.40 (1H, brs), 7.36-7.32 (2H, m), 7.30-7.27 (1H, m), 7.23-7.19 (3H, m), 6.99-6.91 (3H, m), 4.31 (1H, t, *J* = 7.5 Hz), 2.95 (2H, dd, *J* = 7.5, 2.9 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 171.4, 141.6, 137.2, 129.0, 128.4, 128.1, 127.9, 127.3, 126.7, 123.5, 116.0, 42.1, 38.5.



2ad


1,4-Dimethyl-3,4-dihydroquinolin-2(1H)-one (2ad)^[22]: colorless oil, 22.8 mg, 53%,

^1H NMR (400 MHz, CDCl_3) δ 7.28-7.24 (1H, m), 7.20 (1H, d, $J = 7.4$ Hz), 7.05 (1H, d, $J = 7.5, 1.1$ Hz), 6.99 (1H, d, $J = 8.1$ Hz), 3.37 (3H, s), 3.08-3.03 (1H, m), 2.73 (1H, dd, $J = 15.8, 5.5$ Hz), 2.45 (1H, dd, $J = 15.8, 7.6$ Hz), 1.28 (3H, d, $J = 7.0$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 170.0, 139.8, 131.1, 127.4, 126.2, 123.1, 114.8, 39.2, 30.3, 29.5, 19.3.



2ae

4-Methyl-1-phenyl-3,4-dihydroquinolin-2(1H)-one (2ae) ^[23]: white solid, m.p. = 102.0-102.9 $^{\circ}\text{C}$, 46.2 mg, 78%, ^1H NMR (400 MHz, CDCl_3) δ 7.54-7.50 (2H, m), 7.45-7.41 (1H, m), 7.27-7.24 (3H, m), 7.08-7.01 (2H, m), 6.41-6.39 (1H, m), 3.27-3.19 (1H, m), 2.94 (1H, dd, $J = 15.6, 5.4$ Hz), 2.65 (1H, dd, $J = 15.6, 7.1$ Hz), 1.42 (3H, d, $J = 7.0$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 169.7, 140.9, 138.5, 130.8, 129.9, 129.1, 128.2, 127.2, 126.4, 123.3, 117.4, 39.6, 30.8, 19.7.




2af

1-(4-Methoxyphenyl)-4-methyl-3,4-dihydroquinolin-2(1H)-one (2af): white solid, m.p. = 108.0-109.8 $^{\circ}\text{C}$, 21.8 mg, 42%, ^1H NMR (400 MHz, CDCl_3) δ 7.25-7.23 (1H, m), 7.16-7.12 (2H, m), 7.08-7.00 (4H, m), 6.43 (1H, dd, $J = 7.8, 1.5$ Hz), 3.86 (3H, s),

3.23-3.18 (1H, m), 2.91 (1H, dd, $J = 15.6, 5.4$ Hz), 2.63 (1H, dd, $J = 15.6, 7.2$ Hz), 1.40 (3H, d, $J = 7.0$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 170.0, 159.3, 141.1, 131.0, 130.7, 130.0, 127.2, 126.4, 123.2, 117.3, 115.3, 55.6, 39.7, 30.8, 19.8.


HRMS-ESI (m/z): $[\text{M}+\text{Na}]^+$ calcd for $[\text{C}_{17}\text{H}_{17}\text{NNaO}_2]^+$: 290.1151, found: 290.1148.



2ag

1-(3-Methoxyphenyl)-4-methyl-3,4-dihydroquinolin-2(1H)-one (2ag): colorless oil, 18.3 mg, 29%, ^1H NMR (400 MHz, CDCl_3) δ 7.42 (1H, t, $J = 8.1$ Hz), 7.26-7.23 (1H, m), 7.08-7.01 (2H, m), 6.97 (1H, ddd, $J = 8.4, 2.4, 0.7$ Hz), 6.83-6.81 (1H, m), 6.77 (1H, t, $J = 2.1$ Hz), 6.43 (1H, dd, $J = 7.7, 1.5$ Hz), 3.81 (3H, s), 3.24-3.19 (1H, m), 2.92 (1H, dd, $J = 15.6, 5.4$ Hz), 2.64 (1H, dd, $J = 15.6, 7.2$ Hz), 1.41 (3H, d, $J = 7.0$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 169.7, 160.9, 140.8, 139.6, 130.7, 130.6, 127.2, 126.4, 123.4, 121.2, 117.4, 114.6, 114.3, 55.5, 39.7, 30.8, 19.8.

HRMS-ESI (m/z): $[\text{M}+\text{Na}]^+$ calcd for $[\text{C}_{17}\text{H}_{17}\text{NNaO}_2]^+$: 290.1151, found: 290.1149.




2ah


4-(4-methyl-2-oxo-3,4-dihydroquinolin-1(2H)-yl)benzonitrile (2ah): white solid, m.p. = 96.4-98.1 $^\circ\text{C}$, 16.1 mg, 25%, ^1H NMR (400 MHz, CDCl_3) δ 7.81-7.78 (2H, m), 7.41-7.38 (2H, m), 7.28-7.27 (1H, m), 7.09-7.07 (2H, m), 6.36-6.34 (1H, m), 3.27-3.18

(1H, m), 2.91 (1H, dd, $J = 15.6, 5.3$ Hz), 2.63 (1H, dd, $J = 15.6, 7.1$ Hz), 1.40 (3H, d, $J = 7.0$ Hz), ^{13}C NMR (100 MHz, CDCl_3) δ 169.6, 143.0, 140.0, 133.7, 131.4, 130.1, 127.5, 126.8, 124.2, 118.3, 117.5, 112.0, 39.7, 30.8, 19.7.


HRMS-ESI (m/z): $[\text{M}+\text{Na}]^+$ calcd for $[\text{C}_{17}\text{H}_{14}\text{N}_2\text{NaO}_2]^+$: 285.0998, found: 285.0997.



4-Methyl-3, 4-dihydro-2(1H)-quinolinone (3a): white solid, ^1H NMR (400 MHz, CDCl_3) δ 9.33 (1H, brs), 7.19-7.15 (2H, m), 7.01 (1H, td, $J = 1.0, 7.4$ Hz), 6.86 (1H, d, $J = 7.8$ Hz), 3.12 (0.8H, m), 2.73 (1H, dd, $J = 16.1, 5.7$ Hz), 2.45-2.39 (1H, m), 1.31 (3H, d, $J = 7.1$ Hz).




4-Methyl-3, 4-dihydro-2(1H)-quinolinone (4a): white solid, ^1H NMR (400 MHz, CDCl_3) δ 8.29 (1H, brs), 7.21-7.16 (2H, m), 7.03 (1H, td, $J = 1.1, 7.4$ Hz), 6.79 (1H, d, $J = 7.9$ Hz), 3.13-3.10 (1H, m), 2.73 (0.92H, dd, $J = 16.1, 5.8$ Hz), 2.43 (0.92H, dd, $J = 16.1, 7.3$ Hz), 1.31 (0.63H, d, $J = 7.1$ Hz).




4-Methyl-3, 4-dihydro-2(1H)-quinolinone (5a): white solid, ^1H NMR (400 MHz, CDCl_3) δ 9.37 (1H, brs), 7.20-7.16 (2H, m), 7.02 (1H, t, $J = 7.4$ Hz), 6.87 (1H, d, $J = 7.8$

Hz), 3.16-3.11 (0.1H, m), 2.74 (1H, d, $J = 16.1$ Hz), 2.44 (1H, d, $J = 16.1$ Hz), 1.30 (3H, s).



1ai

N-[2-(1-Methylethenyl)phenyl]acetamide (**1ai**): white solid, m.p. = 49.5-50.6 °C, ^1H NMR (400 MHz, CDCl_3) δ 8.23 (1H, d, $J = 8.2$ Hz), 7.55 (1H, brs), 7.28-7.23 (1H, m), 7.14-7.05 (2H, m), 5.38 (1H, s), 5.02 (1H, s), 2.15 (3H, s), 2.07 (3H, s).



1aj

4-Methyl-*N*-[2-(1-methylethenyl)phenyl]benzenesulfonamide (**1aj**): white solid, m.p. = 75.8-77.0 °C, ^1H NMR (400 MHz, CDCl_3) δ 7.66-7.61 (3H, m), 7.22-7.18 (3H, m), 7.08 (1H, brs), 7.06-6.99 (2H, m), 5.25 (1H, s), 4.67 (1H, d, $J = 0.7$ Hz), 2.34 (3H, s), 1.69 (3H, s).

7. Gram-scale hydroaminocarbonylation

The hydroaminocarbonylation reactions were conducted in a batch reactor (50 ml, Shanghai Yanzheng). Palladium(II) trifluoroacetate (33.2 mg, 0.1 mmol, 1.0 mol%), dppp (1,3-bis(diphenylphosphino)propane) (82.4 mg, 0.2 mmol, 2.0 mmol%), TsOH (*p*-toluenesulfonic acid) (68.8 mg, 0.4 mmol, 4.0 mmol%) was dissolved in 20 ml THF. 2-(Prop-1-en-2-yl) aniline **1a** (1.36 ml, 10 mmol) was added. After that, the reactor was flushed with carbon monoxide for three times and then charged with 3.0 MPa carbon monoxide for 24 h at 80 °C. The products were analyzed with GC-MS with mesitylene as internal standard. The solvent was removed under reduced pressure and the residue


was purified by column chromatography (eluent: 20% ethyl acetate in petroleum ether) to give 4-methyl-3,4-dihydro-2(1*H*)-quinolinone (**2a**) (1.50 g, 93% yield).

8. Discussions on the alternative CO migratory insertion into the Pd-N bond.

While a definitive proof of acylpalladacycle **IV** has yet to be obtained, we proposed the mechanism as shown in **Scheme 4** based on the reported literature.^[24] To our knowledge, examples of CO migratory insertion into the Pd-N bond are scarce, especially for the Pd complexes that can undergo competitive insertion into the Pd-C bonds.

For the migratory insertion of CO in Pd complexes with chelating phosphines, many different pathways have been proposed.^[25] The reaction could occur via **(a)** a four-coordinate intermediate and **(b)** a five-coordinate intermediate, as shown in the scheme below. In the four-coordinate pathway, CO would probably displace the aniline -NH₂. For the five-coordinate pathway, deprotonation of aniline -NH₂ is necessary before the migratory insertion into the Pd-N bond can operate. This deprotonation step is usually achieved by utilizing strong bases such as *t*BuONa and LiHMDS,^[26] and should be sluggish under the current reaction conditions. Given the rapid migratory insertion of CO into the Pd-C bond, we assume that the reaction is most likely to occur through the acylpalladacycle (**IV**) pathway.

Scheme S5. CO migratory insertion.




9. Reference


- [1]. A. B. Pangborn, M. A. Giardello, R. H. Grubbs, R. K. Rosen and F. J. Timmers, *Organometallics*, **1996**, *15*, 1518-1520.
- [2]. N. A. Petasis, S.-P. Lu, E. I. Bzowej, D.-K. Fu, J. P. Staszewski, I. Akritopoulou-Zanze, M. A. Patane, Y.-H. Hu, *Pure Appl. Chem.*, **1996**, *68*, 667-670.
- [3]. T. O. Vieira and H. Alper, *Chem. Commun.*, **2007**, 2710–2711.
- [4]. Z. Zhang, L.-L. Liao, S.-S. Yan, L. Wang, Y.-Q. He, J.-H. Ye, J. Li, Y.-G. Zhi, and D.-G. Yu, *Angew. Chem. Int. Ed.* **2016**, *55*, 7068–7072.
- [5]. H. Fan, P. Pan, Y. Zhang, and W. Wang, *Org. Lett.* **2018**, *20*, 7929–7932.
- [6]. Y. Kim, D. Kim and S. Chang, *Chem. Commun.*, **2021**, *57*, 12309-12312.
- [7]. K. McAulay, E. A. Hoyt, M. Thomas, M. Schimpl, M. S. Bodnarchuk, H. J. Lewis, D. Barratt, D. Bhavsar, D. M. Robinson, M. J. D., D. J. Ogg, G. J. L. Bernardes, R. A. Ward, M. J. Waring, and J. G. Kettle. *J. Am. Chem. Soc.*, **2020**, *142*, 10358–10372.
- [8]. J. B. Campbell Jr., J. W. Firor, and T. V. Davenport, *Synth. Commun.*, **1989**, 13-14, 2265-2272.
- [9] M. Font, B. Cendón, A. Seoane, J. L. Mascareñas, M. Gulías, *Angew. Chem. Int. Ed.*, **2018**, *57*, 8255–8259.
- [10]. L. D. Caspers, P. Finkbeiner, and B. J. Nachtsheim, *Chem. Eur. J.* **2017**, *23*, 2748–2752.
- [11]. WO 2019243533 A1 20191226.
- [12]. H. Yanai, H. Mimura, K. Kawada, T. Taguchi, *Tetrahedron*, **2007**, *63*, 2153–2160.
- [13]. K. Kobayashi, K. Miyamoto, T. Yamase, D. Nakamura, O. Morikawa, and H. Konishi, *Bull. Chem. Soc. Jpn.*, **2006**, *79*, 10, 1580–1584.
- [14] F. Ye and H. Alper, *Adv. Synth. Catal.* **2006**, *348*, 1855–1861.
- [15]. M. Harmata and X. Hong, *Org. Lett.*, **2007**, *9*, 2701-2704.
- [16]. K. Okuro, H. Kai, H. Alper, *Tetrahedron: Asymmetry*, **1997**, *8*, 2307-2309.
- [17]. H. Cao, G. Zhu, L. Sun, G. Chen, X. Ma, X. Luo, and J. Zhu, *Eur. J. Med. Chem.*, **2019**, *183*, 111694.
- [18]. J. Horn, H. Y. Li, S. P. Marsden, A. Nelson, R. J. Shearer, A. J. Campbell, D. House, G. G. Weingarten, *Tetrahedron*, **2009**, *65*, 9002-9007.

- [19]. WO 2017034982 A1 20170302.
- [20]. A. Guarna, F. Machetti, E. G. Occhiato, and D. Scarpi, *J. Med. Chem.*, **2000**, *43*, 3718-3735.
- [21] W. Sun, C.-H. Ling, C.-M. Au, and W.-Y. Yu, *Org. Lett.* **2021**, *23*, 9, 3310–3314.
- [22] X. Liu, A. Hamasaki, Y. Yamane, S. A., T. Ishida, . M. Haruta, and M. Tokunaga, *Catalysis Science & Technology*, **2013**, *3*, 3000-3006.
- [23] Q.-K. Zhao, X. Wu, F. Yang, P.-C. Yan, J.-H. Xie, and Q.-L. Zhou, *Org. Lett.* **2021**, *23*, 3593–3598..
- [24] S. Cai, H. Zhang and H. Huang, *Trends in Chemistry*, **2021**, *3*, 218-230; Consult the references therein for specific cases,
- [25] (a) G. K. Anderson and R. J. Cross, *Acc. Chem. Res.* **1984**, *17*, 67-74; (b) G. P. C. M. Dekker, C. J. Elsevier, K. Vrieze and P. W. N. M. Van Leeuwen, *Organometallics*, **1992**, *11*, 1598-1603; (c) C. S. Shultz, J. Ledford, J. M. DeSimone and M. Brookhart, *J. Am. Chem. Soc.*, **2000**, *122*, 6351-6356.
- [26] (a) J. Louie, F. Paul and J. F. Hartwig, *Organometallics*, 1996, **15**, 2794-2805; (b) G. Mann and J. F. Hartwig, *J. Am. Chem. Soc.*, **1996**, *118*, 13109-13110.


10. NMR spectra




¹H NMR of **1b**




¹H NMR of **1c**




¹H NMR of **1d**




¹H NMR of **1e**




^1H NMR of **1f**




^1H NMR of **1g**




¹H NMR of **1h**




¹H NMR of **1i**




¹H NMR of **1j**




¹H NMR of **1k**




^{13}C NMR of **1k**




^1H NMR of **1l**




¹H NMR of **1m**




¹H NMR of **1n**




¹H NMR of **1o**




¹H NMR of **1p**




¹H NMR of **1q**




¹H NMR of **1r**




^1H NMR of **1s**




^1H NMR of **1t**




¹H NMR of **1u**




¹H NMR of **1v**




¹H NMR of **1w**




¹³C NMR of **1w**




^{19}F NMR of **1w**




^1H NMR of **1x**




^{13}C NMR of **1x**




^{19}F NMR of **1x**




¹H NMR of **1y**




¹H NMR of **1z**




¹³C NMR of **1z**




¹⁹F NMR of **1z**




¹H NMR of 1aa




¹H NMR of 1ab




¹H NMR of **1ac**




¹H NMR of **1ad**




$^1\text{H NMR}$ of 1ae




$^1\text{H NMR}$ of 1af




^1H NMR of **1ag**




^{13}C NMR of **1ag**




¹H NMR of 1ah




¹³C NMR of 1ah




¹H NMR of **1a-CD₃**




¹H NMR of **2a**




^{13}C NMR of **2a**




^1H NMR of **2b**




¹³C NMR of 2b




¹H NMR of 2c




^{13}C NMR of **2c**




^1H NMR of **2d**




¹³C NMR of 2d




¹H NMR of 2e




^{13}C NMR of **2e**




^1H NMR of **2f**




^{13}C NMR of **2f**




^1H NMR of **2g**




^{13}C NMR of **2g**




^1H NMR of **2h**




¹³C NMR of **2h**




¹⁹F NMR of **2h**




¹H NMR of **2i**




¹³C NMR of **2i**




^1H NMR of **2j**




^{13}C NMR of **2j**




¹H NMR of **2k**




¹³C NMR of **2k**




¹H NMR of 2I




¹³C NMR of 2I




¹H NMR of 2m




¹³C NMR of 2m




¹H NMR of 2n




¹³C NMR of 2n




^{19}F NMR of **2n**




^1H NMR of **2o**




¹³C NMR of **2o**




¹⁹F NMR of **2o**




^1H NMR of **2p**




^{13}C NMR of **2p**




^{19}F NMR of **2p**




^1H NMR of **2q**




¹³C NMR of **2q**




¹⁹F NMR of **2q**




¹H NMR of **2r**




¹³C NMR of **2r**




^{19}F NMR of **2r**




^1H NMR of **2s**




^{13}C NMR of **2s**




^1H NMR of **2t**




^{13}C NMR of **2t**




^1H NMR of **2u**




^{13}C NMR of **2u**




^1H NMR of **2v**




¹³C NMR of **2v**




¹H NMR of **2w**




¹³C NMR of **2w**




¹⁹F NMR of **2w**




¹H NMR of 2x




¹³C NMR of 2x




^{19}F NMR of **2x**




^1H NMR of **2y**




^{13}C NMR of **2y**




^{19}F NMR of **2y**




¹H NMR of **2z**




¹³C NMR of **2z**




^{19}F NMR of **2z**




^1H NMR of **2aa**




^{13}C NMR of 2aa




^1H NMR of 2ab




^{13}C NMR of 2ab




^1H NMR of 2ac




¹³C NMR of 2ac




¹H NMR of 2ad




^{13}C NMR of 2ad




^1H NMR of 2ae




^{13}C NMR of **2ae**




^1H NMR of **2af**




¹³C NMR of 2af




¹H NMR of 2ag




¹³C NMR of **2ag**




¹H NMR of **2ah**




^{13}C NMR of 2ah



^1H NMR of 3a (Product of hydroaminocarbonylation reactions performed with additional 0.125 ml D_2O and 0.125 ml H_2O)



^1H NMR of **4a** (Product of hydroaminocarbonylation reactions of **1a-CD₃**)



^1H NMR of **5a** (Product of hydroaminocarbonylation reactions performed with additional 0.25 ml D₂O)